REDOXTHERAPIES
RedoxTherapies is a privately held company based on the pioneering adenosine research of founder Michail Sitkovsky, Ph.D. The goal of Redox is to utilize A2 adenosine antagonists to re-activate the otherwise inhibited tumor-reactive T cells, which remain inhibited even after blockade of immunological checkpoint inhibitors. Redox has compiled key assets in this space, including an exclusive license to vipadenant, a potent and selective A2a adenosine receptor antagonist, and intellectual property covering the combination of adenosine antagonists with immuno-modulatory agents.
REDOXTHERAPIES
Industry:
Health Care Pharmaceutical
Founded:
2006-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Status:
Active
Contact:
(617)742-3055
Similar Organizations
Superlative Biosciences
We provide superlative biosciences services.
Unique Pharmaceuticals
Unique Pharmaceuticals provides sterile and non-sterile outsourcing services.
More informations about "RedoxTherapies"
RedoxTherapies - Crunchbase Company Profile & Funding
RedoxTherapies is a privately held company based on the pioneering adenosine research of founder Michail Sitkovsky, Ph.D. The goal of Redox is to utilize A2 adenosine antagonists to re-activate the otherwise inhibited tumor-reactive T cells, which remain inhibited even after …See details»
RedoxTherapies 2025 Company Profile: Valuation, Investors
RedoxTherapies General Information Description. Manufacturer of cancer treatment drugs. The company develops Vipadenant which is an adenosine receptor antagonist for cancer treatment.See details»
RedoxTherapies - Ownership and Business Overview - Mergr
Jul 14, 2016 RedoxTherapies, Inc. is an adenosine research company. Redox is to utilize A2 adenosine antagonists to re-activate the otherwise inhibited tumor-reactive T cells, which …See details»
Redoxtherapies, Inc. Company Profile | Boston, MA | Competitors ...
Find company research, competitor information, contact details & financial data for Redoxtherapies, Inc. of Boston, MA. Get the latest business insights from Dun & Bradstreet.See details»
RedoxTherapies - Products, Competitors, Financials, Employees ...
RedoxTherapies is a company based on the pioneering adenosine research of founder Michail Sitkovsky, Ph.D. The goal of Redox is to utilize A2 adenosine antagonists to re-activate the …See details»
The $10 million molecule: Juno Therapeutics’ …
Jul 15, 2016 Juno paid the $10 million for RedoxTherapies in cash, upfront, with the promise of additional payments when researchers pass undisclosed milestones. Juno announced the acquisition as it resumed ...See details»
Juno Therapeutics Adds Adenosine Receptor Antagonist Through ...
Jul 14, 2016 About Redox Therapies. RedoxTherapies is a privately held company based on the pioneering adenosine research of founder Michail Sitkovsky, Ph.D. The goal of Redox is to …See details»
Juno Therapeutics acquires RedoxTherapies - 2016-07-14
Acquired Organization: RedoxTherapies RedoxTherapies provides pioneering adenosine research. Acquiring Organization: Juno Therapeutics Juno Therapeutics is a clinical-stage …See details»
RedoxTherapies Acquired by Juno Therapeutics for $10M+
Jul 19, 2016 RedoxTherapies is a privately held company based on the pioneering adenosine research of founder Michail Sitkovsky, Ph.D. The goal of Redox is to utilize A2 adenosine …See details»
RedoxTherapies, Inc. - Drug pipelines, Patents, Clinical trials
Explore RedoxTherapies, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»
Redox therapy - Wikipedia
Redox therapy is an experimental therapy [1] [2] that aims to effect an outcome by modifying the levels of pro-oxidant and antioxidant agents in cells. [3] The term "redox" is a contraction of …See details»
Redox regulation: mechanisms, biology and therapeutic targets in ...
Mar 7, 2025 Redox signaling acts as a critical mediator in the dynamic interactions between organisms and their external environment, profoundly influencing both the onset and …See details»
Redox regulation in regenerative medicine and tissue engineering: …
One of the biggest challenges in tissue engineering and regenerative medicine is to incorporate a functioning vasculature to overcome the consequences of a lack of oxygen and nutrients in the …See details»
Potential of redox therapies in neurodegenerative disorders
Mar 1, 2017 Potential of redox therapies in neurodegenerative disorders Front Biosci (Elite Ed). 2017 Mar 1;9(2) :214-234. ... The World Health Organization (WHO) estimates that, by 2040, …See details»
Fundamentals of redox regulation in biology
Apr 30, 2024 A set of fundamental principles of organization of biological redox reactions in living cells and organisms, termed redox code, was formulated in 2015 (ref. 22).Here, the four …See details»
Perspectives in ROS/Redox Regulation Cancer Therapy
Dec 14, 2023 Each tumor (or cancer) is unique in terms of its growth, invasion, metastasis, and redox regulation. Tumor stroma, named as the tumor microenvironment (TME), also plays an …See details»
Redox regulation and its emerging roles in cancer treatment
Jan 15, 2023 Insights into how excessive ROS induce cell death will help guide the future of developing techniques to trigger a therapeutic dose of ROS against cancers [25].The effect of …See details»
New Emerging Therapeutic Strategies Based on Manipulation of …
Nov 6, 2024 Background: Resistance to standard therapeutic methods, including chemotherapy, immunotherapy, and targeted therapy, remains a critical challenge in effective cancer …See details»
Redox organization of living systems - ScienceDirect
May 1, 2024 Redox organization governs an underlying simplicity in living systems. Critically, redox reactions enable the essential characteristics of life: extraction of energy from the …See details»
Potential of redox therapies in neurodegenerative disorders
Recently significant advances have been made to understand the pathophysiological mechanisms of neurodegenerative disorders to provide real therapeutic benefits. There is evidence that …See details»